What happens when a drug is facing patent loss – create a new drug that with time or delayed release properties
Posted Feb 03 2009 12:08am
Now there’s one more alternative medication for GERD, soon to be released from Takeda as Prevacid nears patent expiration. As the article states, choices for treatment of GERD certainly are not limited and this is really nothing new as many drugs have been re-created with the same type of time released actions. BD
Deerfield-based Takeda Pharmaceuticals North America Inc. said Friday evening its heartburn drug Kapidex was approved by the Food and Drug Administration, entering the crowded field of prescription proton pump inhibitors.
The FDA approved Kapidex "delayed release capsules" for the treatment of gastroesophageal reflux disease, commonly known as GERD. Kapidex is in the same proton pump inhibitor class of drugs as Takeda's Prevacid, which loses patent protection later this year and faces competition from cheaper generics.